Article Text

Download PDFPDF
Childhood Interstitial Lung Disease (chILD): shining a new light on childhood!
  1. Alicia Casey1,
  2. Robin Deterding2
  1. 1Division of Pulmonary Medicine, Boston Children's Hospital, Boston, Massachusetts, USA
  2. 2Pediatric Pulmonary Medicine, University of Colorado, Denver, Colorado, USA
  1. Correspondence to Dr Robin Deterding, Pediatric Pulmonary Medicine, University of Colorado, Denver, CO 80045, USA; robin.Deterding{at}

Statistics from

Childhood interstitial and diffuse lung diseases (chILD) are a heterogeneous and diverse group of rare lung disorders presenting in childhood. Unfortunately, there are few therapies and poor understanding of the natural history for most disorders. Patients encounter high morbidity and mortality. Through the establishment of national research networks and registries such as chILD EU in the European Union, chILD Research Network in the USA and the chILDRANZ: children’s interstitial lung disease research in Australia and New Zealand, progress has begun to better understand patients with chILD. The chILD EU group published two landmark manuscripts in Thorax demonstrating the value of these registries to further advance the care of these patients through evidence-based studies.

Defining acute exacerbations (AEs) and understanding their clinical impact and outcome is essential to moving chILD research forward. Seidl et al in their manuscript ‘Acute Exacerbations in Children’s Interstitial Lung Disease-A chILD-EU Cohort Study’1 provides a definition for chILD AEs that can be used as standardised criteria in future …

View Full Text


  • Twitter @LungDoc4Kids

  • Contributors AC and RD equally produced the manuscript.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests RD is a consultant for Boehringer Ingelheim Inc for Pediatric Interstitial Lung Disease. She is the International Coordinating Investigator for a pediatric interstitial lung disease clinical trial with this company.

  • Provenance and peer review Commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles

  • Interstitial lung disease
    Elias Seidl Nicolaus Schwerk Julia Carlens Martin Wetzke Steve Cunningham Nagehan Emiralioğlu Nural Kiper Joanna Lange Katarzyna Krenke Nicola Ullmann Dora Krikovszky the chILD-EU collaborators Phillen Maqhuzu Charlotte A Griese Larissa Schwarzkopf Matthias Griese
  • Paediatric lung disease
    Elias Seidl Nicolaus Schwerk Julia Carlens Martin Wetzke Nagehan Emiralioğlu Nural Kiper Joanna Lange Katarzyna Krenke Zsolt Szepfalusi Florian Stehling Winfried Baden Susanne Hämmerling Silvija-Pera Jerkic Marijke Proesmans Nicola Ullmann Frederik Buchvald Katrin Knoflach Matthias Kappler the chILD EU collaborators Matthias Griese